Seminal pay for delay law opposed by pharma companies
Generics and innovator companies say they don’t like the new and ‘badly-worded’ legislation introduced by California that bans drug settlements and could actually raise drug prices. Read more...
AI alliances will push pharma refocus on patent bundles and licensing
Pharma companies say AI’s potential to make R&D models more efficient and less expensive will drive the development of therapeutics that require different IP strategies. Read more...
Energy digitalisation spurs industry IP overhaul
SBM Offshore and IFP Energies explain how the energy sector has embraced digital technologies such as AI to drive efficiencies – and how that move is creating data rights and eligibility challenges. Read more...
